Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia

Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) are highly prevalent in older men. Medical therapy is the first-line treatment for LUTS associated with BPH. Mainstays in the treatment of male LUTS and clinical BPH are the α1-adrenergic receptor antagonists. Silodosin is a new α1-adrenergic receptor antagonist that is selective for the α1A-adrenergic receptor. By antagonizing α1A-adrenergic receptors in the prostate and urethra, silodosin causes smooth muscle relaxation in the lower urinary tract. Since silodosin has greater affinity for the α1A-adrenergic receptor than for the α1B-adrenergic receptor, it minimizes the propensity for blood pressure-related adverse effects caused by α1B-adrenergic receptor blockade. In the clinical studies, patients receiving silodosin at a total daily dose of 8 mg exhibited significant improvements in the International Prostate Symptom Score and maximum urinary flow rate compared with those receiving placebo. Silodosin showed early onset of efficacy for both voiding and storage symptoms. Furthermore, long-term safety of silodosin was also demonstrated. Retrograde or abnormal ejaculation was the most commonly reported adverse effect. The incidence of orthostatic hypotension was low. In conclusion, silodosin, a novel selective α1A-adrenergic receptor antagonist, was effective in general and without obtrusive side effects. This review provides clear evidence in support of the clinical usefulness of silodosin in the treatment of LUTS associated with BPH.

[1]  Y. Funahashi,et al.  Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study. , 2009, The Journal of urology.

[2]  L. Hill,et al.  Rapid efficacy of the highly selective α(1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. , 2009, The Journal of urology.

[3]  T. Tammela,et al.  Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. , 2011, European urology.

[4]  C. Roehrborn,et al.  Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH , 2010, Prostate Cancer and Prostatic Diseases.

[5]  Y. Homma,et al.  Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia. , 2010, Urology.

[6]  E. Yokoyama,et al.  Short‐term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia , 2010, International journal of urology : official journal of the Japanese Urological Association.

[7]  Ken‐ichiro Yoshida,et al.  Urodynamic effects of silodosin, a new α1A‐adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia , 2007, Neurourology and urodynamics.

[8]  L. Hill,et al.  Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study. , 2009, Urology.

[9]  L. Hill,et al.  Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. , 2009, The Journal of urology.

[10]  D. Weinberger,et al.  Intraoperative floppy iris syndrome: possible relationship with alpha-1 adrenergic receptor antagonists. , 2009, The Israel Medical Association journal : IMAJ.

[11]  N. Masumori,et al.  Inhibition of Seminal emission is the main cause of anejaculation induced by a new highly selective alpha1A-blocker in normal volunteers. , 2008, The journal of sexual medicine.

[12]  S. Fine,et al.  Alpha-Adrenergic Receptor Antagonists in Older Patients With Benign Prostatic Hyperplasia: Issues and Potential Complications , 2008, The Journal of the American Osteopathic Association.

[13]  M. Emberton,et al.  Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management , 2008, International journal of clinical practice.

[14]  J. L. Edwards.  Diagnosis and management of benign prostatic hyperplasia. , 2008, American family physician.

[15]  C. Roehrborn,et al.  α1‐Adrenoceptor subtypes and lower urinary tract symptoms , 2008, International journal of urology : official journal of the Japanese Urological Association.

[16]  G. Tsujimoto,et al.  α1‐Adrenoceptors are required for normal male sexual function , 2007 .

[17]  M. C. Michel.  α1‐Adrenoceptors and ejaculatory function , 2007 .

[18]  C. Cheung,et al.  Incidence of intraoperative floppy iris syndrome in patients on either systemic or topical alpha1-adrenoceptor antagonist. , 2007, American journal of ophthalmology.

[19]  Y. Homma,et al.  Silodosin, a new α1A‐adrenoceptor‐selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo‐controlled, double‐blind study in Japanese men , 2006, BJU international.

[20]  T. Tsukamoto,et al.  Ejaculatory disorder caused by alpha‐1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission , 2006, International journal of urology : official journal of the Japanese Urological Association.

[21]  N. Wasserman.  Benign prostatic hyperplasia: a review and ultrasound classification. , 2006, Radiologic clinics of North America.

[22]  聡 立道,et al.  シロドシン(KMD-3213)のα1-アドレナリン受容体サブタイプ選択性及び臓器特異性 , 2006 .

[23]  Y. Yamazaki.  Development of Silodosin , 2006 .

[24]  聡 立道,et al.  ラットのフェニレフリン誘発尿道内圧上昇及び血圧に対するシロドシン （KMD-3213）の作用—下部尿路選択性の検討— , 2006 .

[25]  Y. Yamazaki,et al.  [Alpha1-adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213)]. , 2006, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[26]  Y. Yamazaki,et al.  [Effects of silodosin (KMD-3213) on phenylephrine-induced increase in intraurethral pressure and blood pressure in rats--study of the selectivity for lower urinary tract]. , 2006, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[27]  F. Cogé,et al.  Update on human α1-adrenoceptor subtype signaling and genomic organization , 2004 .

[28]  F. Cogé,et al.  Update on human alpha1-adrenoceptor subtype signaling and genomic organization. , 2004, Trends in pharmacological sciences.

[29]  C. Cooper,et al.  Use of α‐blockers and the risk of hip/femur fractures , 2003, Journal of internal medicine.

[30]  M. O'Leary.  Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications. , 2003, Urology.

[31]  C. Schulman.  Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment. , 2003, Urology.

[32]  M. Ishiguro,et al.  Identification of binding sites of prazosin, tamsulosin and KMD-3213 with alpha(1)-adrenergic receptor subtypes by molecular modeling. , 2002, Life sciences.

[33]  C. Roehrborn,et al.  Benign prostatic hyperplasia. , 2020, BMJ.

[34]  Bradford D. Winters,et al.  Subtype Specific Regulation of Human Vascular α1-Adrenergic Receptors by Vessel Bed and Age , 1999 .

[35]  S. Tatemichi,et al.  KMD-3213, a uroselective and long-acting alpha(1a)-adrenoceptor antagonist, tested in a novel rat model. , 1999, The Journal of pharmacology and experimental therapeutics.

[36]  J. Oesterling,et al.  Alpha-blockade therapy for benign prostatic hyperplasia: from a nonselective to a more selective alpha1A-adrenergic antagonist. , 1998, Urology.

[37]  G. Tsujimoto,et al.  Quantification and distribution of α1‐adrenoceptor subtype mRNAs in human proximal urethra , 1998, British journal of pharmacology.

[38]  M. Wyllie,et al.  Prostatic α1‐adrenoceptors and uroselectivity , 1997 .

[39]  H. Lepor,et al.  Prostatic alpha 1-adrenoceptors and uroselectivity. , 1997, The Prostate.

[40]  G. Tsujimoto,et al.  KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. , 1995, Molecular pharmacology.

[41]  R. Lefkowitz,et al.  International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update. , 1995, Pharmacological reviews.

[42]  D J Parry-Smith,et al.  Cloning and pharmacological characterization of human alpha-1 adrenergic receptors: sequence corrections and direct comparison with other species homologues. , 1995, The Journal of pharmacology and experimental therapeutics.

[43]  M. Caron,et al.  Localization of mRNA for three distinct alpha 1-adrenergic receptor subtypes in human tissues: implications for human alpha-adrenergic physiology. , 1994, Molecular pharmacology.

[44]  M. Caron,et al.  Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate. , 1993, The Journal of urology.